AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34607784
Drug: Intra-oral LED
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-oral LED device with a wavelength of 640nm and a power density of 40 mW/cm2, used 5 minutes per day.
Trial: 34607784
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment using a coated light cure device, following the same protocol as the laser group.
Trial: 33844996
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (400 µg per actuation, 2 inhalations twice a day until symptom resolution)
Trial: 35286860
Drug: Inhaled 7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 7% hypertonic saline
Trial: 33734828
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atomoxetine + 2 mg biperiden hydrochloride (ato-bip)
Trial: 32239737
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injection
Trial: 34241801
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (FS Tablets, 0.9 g/d)
Trial: 32716700
Drug: FDA-approved vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved vaccines with postapproval safety-related label modifications
Trial: 32716700
Drug: FDA-approved vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved vaccines without postapproval safety-related label modifications
Trial: 34705137
Drug: Early Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Botulinum toxin injection (50 U) administered 1 week before surgery
Trial: 34328630
Drug: 90 mcg
RxNorm normalized name: Linzess 290 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mcg ropeginterferon alfa-2b
Trial: 34328630
Drug: 180 mcg
RxNorm normalized name: Igalmi 180 MCG Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mcg ropeginterferon alfa-2b
Trial: 34328630
Drug: 270 mcg
RxNorm normalized name: Ascorbic Acid/Biotin/Cyanocobalamin/Folic Acid/Iron/Lactobacillus casei/Niacin/Pantothenic Acid/Pyridoxine/Riboflavin/Thiamine 75 MG-270 MCG-12 MCG-1250 MCG-130 MG-6 BILLION CFU-10 MG-10 MG-10 MG-3 MG-2 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mcg ropeginterferon alfa-2b
Trial: 34328630
Drug: ropeginterferon alfa-2b
RxNorm normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ropeginterferon alfa-2b (all doses)
Trial: 33033021
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral feeding formula (1.5 kcal/mL, 54% carbohydrate)
Trial: 33033021
Drug: Lower carbohydrate
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower carbohydrate isocaloric enteral feeding formula (1.5 kcal/mL, 28% carbohydrate)
Trial: 35810754
Drug: Bendamustine-rituximab (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine-rituximab (group B) with bendamustine at 90 mg/m2 on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 1 of cycles 2–6, administered intravenously.
Trial: 33957649
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream applied to the cervix weekly for 12 weeks
Trial: 33957649
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment prior to LEEP)
Trial: 39001910
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC)
Trial: 33878154
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) followed by Golimumab (GLM) 50 mg every 4 weeks during the OLE
Trial: 35820904
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser needle acupuncture treatment
Trial: 34282645
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) integrated with activity pacing for 6 sessions by a trained oncology nurse
Trial: 32818112
Drug: Oral BI
RxNorm normalized name: Osteo Bi-Flex Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BI 1026706 100 mg twice daily for 12 weeks
Trial: 38041077
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant chemotherapy
Trial: 34753304
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) in BASICS trial centers
Trial: 32415231
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy protocol based on Pivotal Response Treatment (PRT)
Trial: 35452104
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody postexposure prophylaxis (PEP) with casirivimab and imdevimab
Trial: 32593257
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy + audiovisual correction
Trial: 32593257
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy + audiovisual correction + testosterone undecanoate
Trial: 32593257
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy and escitalopram / tofisopam
Trial: 34358777
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2, oral prednisone 5 mg twice daily, and oral enzalutamide 160 mg/d (arm DE)
Trial: 34358777
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 and oral prednisone 5 mg twice daily (arm D)
Trial: 34033270
Drug: Prazosin, uptitrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin, uptitrated to 16 mg/d
Trial: 35174663
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg
Trial: 33214044
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) to prostate and pelvis, dose delivered was 35–37.5 Gy to prostate and gross node, 25 Gy in five fractions to elective pelvic nodal region.
Trial: 32555938
Drug: Microtexturized silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtexturized silicone implants (Lifesil®)
Trial: 33360345
Drug: SMDS combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMDS combined with aspirin
Trial: 32163097
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m2) followed by maintenance Pemetrexed (500 mg/m2) every 3 weeks
Trial: 32163097
Drug: Docetaxel monotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel monotherapy (60 mg/m2) every 3 weeks
Trial: 35514254
Drug: Reference linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference linagliptin formulation (5 mg) under fed conditions
Trial: 34348455
Drug: Clofarabine 5x40
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine 5x40 mg/m2 + PEG-ASP 2,500 IU/m2
Trial: 34348455
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HIDAC) 4x3g/m2 + PEG-ASP 2,500 IU/m2
Trial: 34348455
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine + PEG-ASP
Trial: 33653909
Drug: High-Flow Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Oxygen Therapy (HFT)
Trial: 32979314
Drug: WONDFO SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China)
Trial: 36897521
Drug: Individual formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual formulations (Ezetimibe and Rosuvastatin)
Trial: 36897521
Drug: Ezetimibe/Rosuvastatin fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Rosuvastatin fixed dose combination (10 mg/10 mg)
Trial: 32301407
Drug: Cranberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry beverage (450 ml daily for 8 weeks)
Trial: 32365398
Drug: Metformin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1500 mg/day)
Trial: 35796392
Drug: Prednisone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 0.5 mg/kg/day orally for 7 days, followed by a decreasing dosage for another week
Trial: 35796392
Drug: Intranasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroid therapy
Trial: 32653606
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of mifepristone every other day for two months followed by insertion of an LNG-IUS 52 mg
Trial: 36387992
Drug: 3 60‐min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 60‐min sessions of Brief Prolonged Exposure Therapy (Brief PE)
Trial: 33154284
Drug: Intravenous hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine 10 mg every 30 min up to 5 doses
Trial: 33154284
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine 20 mg every 30 min up to 5 doses
Trial: 33154284
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine and intravenous hydralazine
Trial: 35450742
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg per day
Trial: 34544853
Drug: Task-specific motor
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-specific motor therapy (20 extra hours) starting at ≤30 days after stroke (acute)
Trial: 34544853
Drug: Task-specific motor
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-specific motor therapy (20 extra hours) starting at 2 to 3 months after stroke (subacute)
Trial: 34544853
Drug: Task-specific motor
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-specific motor therapy (20 extra hours) starting at ≥6 months after stroke (chronic)
Trial: 33431304
Drug: Micro-dosed carbohydrate-electrolyte
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-dosed carbohydrate-electrolyte solution
Trial: 32350650
Drug: Consideration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consideration of prismatic side-effects of spectacle lenses and eye ball length in dosage planning (intervention group)
Trial: 32350650
Drug: No consideration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No consideration of prismatic side-effects of spectacle lenses and eye ball length in dosage planning (control group)
Trial: 35172056
Drug: EDP-938 600
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-938 600 mg once daily
Trial: 35172056
Drug: EDP-938 300
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-938 300 mg twice daily after a 500 mg loading dose
Trial: 34098518
Drug: Daridorexant (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant (50 mg)
Trial: 34098518
Drug: Daridorexant (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant (50 mg) + Citalopram (20 mg at steady state)
Trial: 35898486
Drug: Daily finger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily finger gymnastics; exercise 2-3 times per day, ibuprofen sustained-release capsules if excessive pain occurs.
Trial: 34416778
Drug: Ibuprofen enema
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen enema
Trial: 34416778
Drug: Both ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both ibuprofen enema and suppository
Trial: 33375952
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine (BUP) 0.02 mg/kg IM
Trial: 33375952
Drug: Sustained-release buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release buprenorphine (BSR) 0.2 mg/kg SC
Trial: 35747181
Drug: 2-dose measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose measles vaccination (MV) with no C-OPV
Trial: 35747181
Drug: 2-dose measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose measles vaccination (MV) at 4 months with maternal measles antibodies (MatAb)
Trial: 32966722
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zinc sulfate for 14 days
Trial: 32966722
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zinc sulfate for 14 days
Trial: 32966722
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zinc sulfate for 14 days
Trial: 34856936
Drug: Avelumab combined
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab combined with dose-dense methotrexate-vinblastine-doxorubicin-cisplatin
Trial: 35284778
Drug: Emicizumab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 1.5 mg/kg once weekly (arm A)
Trial: 35284778
Drug: Emicizumab 6
RxNorm normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 6 mg/kg every 4 weeks (arm B)
Trial: 34482179
Drug: Tomuzotuximab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomuzotuximab (initial dose 990 mg then 720 mg) weekly with cisplatin 100 mg/m2 and fluorouracil (5-FU; 1000 mg/m2/day, days 1-4) every 3 weeks
Trial: 34482179
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m2 subsequent 250 mg/m2) weekly with the same chemotherapeutic backbone
Trial: 35040416
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (32 cases)
Trial: 34047716
Drug: PEG with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG with electrolyte (50 mL/kg) and oral bisacodyl (PEG+B group)
Trial: 34047716
Drug: PEG with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG with electrolyte (70 mL/kg) and glycerol enema (PEG+G group)
Trial: 34047716
Drug: PEG+G group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG+G group
Trial: 39641404
Drug: Daridorexant 25
RxNorm normalized name: daridorexant 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 25 mg
Trial: 35960814
Drug: Combined Er:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Er:YAG laser and Nd:YAG laser treatment
Trial: 34366004
Drug: Complex interprofessional
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex interprofessional intervention including drug review by pharmacists, educational sessions for general practitioners and nurses, a drug safety toolbox, and change management seminars for 23 nursing homes with 452 residents.
Trial: 33545941
Drug: Herb-partitioned moxibustion
RxNorm normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herb-partitioned moxibustion plus lifestyle modification treatment
Trial: 34140144
Drug: Conventional-dose SRT
RxNorm normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose SRT (64 Gy)
Trial: 34140144
Drug: Dose-intensified SRT
RxNorm normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensified SRT (70 Gy)
Trial: 32783554
Drug: Standard-Dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose CT (SDCT)
Trial: 34229149
Drug: amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin
Trial: 35363318
Drug: Ruxolitinib 10
RxNorm normalized name: ruxolitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 10 mg twice daily (n = 165)
Trial: 35363318
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (BAT) (n = 164)
Trial: 36652465
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors
Trial: 35951014
Drug: 0.5% EGCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% EGCG (10 mg/kg daily dose)
Trial: 35233908
Drug: ertugliflozin 15
RxNorm normalized name: ertugliflozin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ertugliflozin 15 mg
Trial: 616863419
Drug: Gymnema sylvestre
RxNorm normalized name: GYMNEMA SYLVESTRE LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gymnema sylvestre (GS) treatment
Trial: 36131291
Drug: Metformin (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (initiated at 500mg/day, titrated to a maximum of 2500mg over 10 days)
Trial: 32036242
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of CBD (Epidiolex® or Epidyolex®)
Trial: 36336841
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg every 3 weeks)
Trial: 34215316
Drug: Bazedoxifene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (20 mg/day) with elemental calcium 1200 mg and vitamin D 800 IU daily
Trial: 34215316
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcium 1200 mg and vitamin D 800 IU only)
Trial: 34939373
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg/day)
Trial: 32641163
Drug: Hydroxychloroquine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 800 mg orally in two doses followed by 400 mg daily in two doses and azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group)
Trial: 39602203
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control group
Trial: 38650969
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (BB)
Trial: 33879151
Drug: Unauthorized trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unauthorized trials with mismatched therapeutic indications, posology, or administration method
Trial: 33879151
Drug: Unauthorized trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unauthorized trial including a drug therapy intervention with an unapproved active substance
Trial: 32458778
Drug: Recent antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent antibiotic use
Trial: 32151878
Drug: NC Gut
RxNorm normalized name: codeine phosphate / pseudoephedrine hydrochloride / triprolidine hydrochloride Oral Solution [Poly Hist NC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NC Gut Relief Formula (5 g/d for 4 weeks, then 10 g/d for 4 weeks)
Trial: 35666250
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) program, 10 sessions
Trial: 32546726
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard chemotherapy)
Trial: 33403699
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Vancomycin
Trial: 35667569
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (SM)
Trial: 34449946
Drug: Vitrification treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrification treatment + 5?M of Retinol
Trial: 35851518
Drug: Single session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session of Botulinum toxin A injection
Trial: 35851518
Drug: Multiple sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple sessions of multivitamins mesotherapy injection
Trial: 36443174
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg then 25 mg x 5 doses)